Cargando…
Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases
Cardiovascular disease is the most common health problem worldwide and remains the leading cause of morbidity and mortality. Despite recent advances in the management of cardiovascular diseases, pharmaceutical treatment remains suboptimal because of poor pharmacokinetics and high toxicity. However,...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512262/ https://www.ncbi.nlm.nih.gov/pubmed/36172197 http://dx.doi.org/10.3389/fphar.2022.999404 |
_version_ | 1784797814624092160 |
---|---|
author | Yang, Fangyu Xue, Jianjiang Wang, Guixue Diao, Qizhi |
author_facet | Yang, Fangyu Xue, Jianjiang Wang, Guixue Diao, Qizhi |
author_sort | Yang, Fangyu |
collection | PubMed |
description | Cardiovascular disease is the most common health problem worldwide and remains the leading cause of morbidity and mortality. Despite recent advances in the management of cardiovascular diseases, pharmaceutical treatment remains suboptimal because of poor pharmacokinetics and high toxicity. However, since being harnessed in the cancer field for the delivery of safer and more effective chemotherapeutics, nanoparticle-based drug delivery systems have offered multiple significant therapeutic effects in treating cardiovascular diseases. Nanoparticle-based drug delivery systems alter the biodistribution of therapeutic agents through site-specific, target-oriented delivery and controlled drug release of precise medicines. Metal-, lipid-, and polymer-based nanoparticles represent ideal materials for use in cardiovascular therapeutics. New developments in the therapeutic potential of drug delivery using nanoparticles and the application of nanomedicine to cardiovascular diseases are described in this review. Furthermore, this review discusses our current understanding of the potential role of nanoparticles in metabolism and toxicity after therapeutic action, with a view to providing a safer and more effective strategy for the treatment of cardiovascular disease. |
format | Online Article Text |
id | pubmed-9512262 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95122622022-09-27 Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases Yang, Fangyu Xue, Jianjiang Wang, Guixue Diao, Qizhi Front Pharmacol Pharmacology Cardiovascular disease is the most common health problem worldwide and remains the leading cause of morbidity and mortality. Despite recent advances in the management of cardiovascular diseases, pharmaceutical treatment remains suboptimal because of poor pharmacokinetics and high toxicity. However, since being harnessed in the cancer field for the delivery of safer and more effective chemotherapeutics, nanoparticle-based drug delivery systems have offered multiple significant therapeutic effects in treating cardiovascular diseases. Nanoparticle-based drug delivery systems alter the biodistribution of therapeutic agents through site-specific, target-oriented delivery and controlled drug release of precise medicines. Metal-, lipid-, and polymer-based nanoparticles represent ideal materials for use in cardiovascular therapeutics. New developments in the therapeutic potential of drug delivery using nanoparticles and the application of nanomedicine to cardiovascular diseases are described in this review. Furthermore, this review discusses our current understanding of the potential role of nanoparticles in metabolism and toxicity after therapeutic action, with a view to providing a safer and more effective strategy for the treatment of cardiovascular disease. Frontiers Media S.A. 2022-09-12 /pmc/articles/PMC9512262/ /pubmed/36172197 http://dx.doi.org/10.3389/fphar.2022.999404 Text en Copyright © 2022 Yang, Xue, Wang and Diao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Yang, Fangyu Xue, Jianjiang Wang, Guixue Diao, Qizhi Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases |
title | Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases |
title_full | Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases |
title_fullStr | Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases |
title_full_unstemmed | Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases |
title_short | Nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases |
title_sort | nanoparticle-based drug delivery systems for the treatment of cardiovascular diseases |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512262/ https://www.ncbi.nlm.nih.gov/pubmed/36172197 http://dx.doi.org/10.3389/fphar.2022.999404 |
work_keys_str_mv | AT yangfangyu nanoparticlebaseddrugdeliverysystemsforthetreatmentofcardiovasculardiseases AT xuejianjiang nanoparticlebaseddrugdeliverysystemsforthetreatmentofcardiovasculardiseases AT wangguixue nanoparticlebaseddrugdeliverysystemsforthetreatmentofcardiovasculardiseases AT diaoqizhi nanoparticlebaseddrugdeliverysystemsforthetreatmentofcardiovasculardiseases |